Solstice Advanced Materials, Inc. SOLS
Composite 39/100; the shares have moved about 58% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 17/100 — a strong mark against it.
Balance-sheet strength ranks 58/100 — a slight point in its favour. Quality ranks 50/100 — a slight point in its favour.
Momentum ranks 17/100 — a strong mark against it. Growth ranks 22/100 — a strong mark against it. Valuation ranks 36/100 — a moderate mark against it.
What the company does Solstice Advanced Materials (SOLS) develops and sells low global warming potential refrigerants, specialty chemicals, and advanced materials for electronics, defense, and pharmaceutical markets under brands like Solstice, Genetron, and Aclar.
Key financials SOLS reports gross margins of 31.3%, operating margins of 18.2%, and net margins of 4.7%. ROE is 10.7%, ROA 8.6%, and ROCE 15.7%. Revenue grew 10.6% year-over-year, while EPS declined -37.2%. Debt/Equity stands at 1.65 with a current ratio of 1.43.
Stock health The stock is down -36.74% from its 52-week high, with 3-month and 6-month declines of -25.36% and -12.31%, respectively. RSI(14) is 34.60, indicating oversold conditions. Sideravia scores it 45.2 overall, with Valuation at 43.6 and Growth at 23.6.
Price vs fair value SOLS trades at a PREMIUM of 9.40% versus our fair-value estimate of 52.01 and at a discount of 41.64% versus the analyst 12-month target of 81.29. - Simply Wall St notes SOLS remains pricey despite a 35% slump (Simply Wall St.) - Earnings call highlights strong sales growth in Q2 2026 (GuruFocus.com) - Barrons suggests infrastructure earnings, including SOLS, counter AI spending fears (Barrons.com)
Looking forward Forward P/E is 22.68 with a PEG of 0.18, suggesting potential undervaluation relative to growth. Analysts project an 81.29 target, implying significant upside from current levels.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.